Contact this trialFirst, we need to learn more about you.
PI3K inhibitor
Copanlisib + Ibrutinib for Central Nervous System Lymphoma
Recruiting1 awardPhase 1 & 2
West Harrison, New York
This trial is testing the safety of using two drugs, copanlisib and ibrutinib, together. The study focuses on patients with a type of brain and spinal cord cancer called PCNSL. These drugs work by blocking proteins that cancer cells need to grow.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service